<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02606708</url>
  </required_header>
  <id_info>
    <org_study_id>11105</org_study_id>
    <nct_id>NCT02606708</nct_id>
  </id_info>
  <brief_title>Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy</brief_title>
  <official_title>Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the feasibility and tolerability of a&#xD;
      regimen of accelerated (hypofractionated) Intensity Modulated Radiation Therapy (AIMRT) to&#xD;
      the whole breast as part of breast preservation. In addition, the investigators want to&#xD;
      prospectively collect blood specimens to: assess TGF-Î² polymorphisms to identify potential&#xD;
      carriers at higher risk for post-treatment fibrosis; generate a blood specimen repository for&#xD;
      future studies of other relevant polymorphisms. The study investigators also want to&#xD;
      prospectively follow each treated woman yearly to assess long-term radiation sequelae of the&#xD;
      current regimen by using the LENT/SOMA scores.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite level I evidence of comparable efficacy to that of mastectomy, breast conserving&#xD;
      therapy (BCT) remains underutilized in the United States. In 1990, the National Institutes of&#xD;
      Health (NIH) Consensus Development Conference concluded that BCT was the appropriate method&#xD;
      of treatment for the majority of women with early stage I and II breast cancer. However, this&#xD;
      subsequently only translated in a moderate increase in the utilization of BCT, shifting from&#xD;
      34% to 60% for stage I breast cancer and from 19% to 39% for stage II breast cancer.&#xD;
&#xD;
      There appear to be multiple causes for underutilization. The demands of the standard&#xD;
      radiation schedule probably play the main role. Generally, post-lumpectomy radiation therapy&#xD;
      consists of 4 to 5 weeks of whole breast radiation of a total dose 45 to 50 Gy in 23-25&#xD;
      fractions, usually followed by a boost of 10 to 16 Gy in 5-8 fractions to the tumor bed area.&#xD;
      The total length of treatment is 5-7 weeks, commonly six weeks. Practically, women who choose&#xD;
      BCT automatically commit to a regimen of approximately six weeks of daily radiation visits&#xD;
      (Monday to Friday) to complete the local management of their breast cancer. For many women,&#xD;
      concerns about this commitment are likely to influence the choice for mastectomy instead of&#xD;
      breast preservation since only 40-60% of women who meet criteria for BCT actually undergo the&#xD;
      procedure. In addition to possible biases of the primary health care provider affecting these&#xD;
      choices, it is known that distance from RT treatment facilities also plays an important role&#xD;
      in women's choice for mastectomy instead of BCT. Unfortunately, 15-30% of patients who have&#xD;
      actually selected BCT, in particularly older patients and those with 2 or more co-morbid&#xD;
      conditions, do not receive postoperative RT. These facts warrant a critical assessment of&#xD;
      standard radiation therapy in this clinical setting.&#xD;
&#xD;
      The actual standard approach to post-segmental mastectomy adjuvant radiation at our&#xD;
      institution consists of surgical excision followed by 6 weeks of breast irradiation for a&#xD;
      total of 30 fractions of 2 Gy each, 23 (46 Gy) to the whole breast while 7 to the original&#xD;
      tumor bed (14 Gy). Instead, the women in this study will only receive 15 larger radiation&#xD;
      fractions (2.7 Gy) to the entire breast with a concomitant boost to the tumor bed (2.7 Gy +&#xD;
      .5 Gy, total 3.2 Gy per fraction). All women will be treated prone to best apply IMRT&#xD;
      techniques while avoiding the rest of the body.&#xD;
&#xD;
      Treatment with fewer fractions over a shorter duration of time offers several advantages,&#xD;
      provided it is as effective as the conventional treatment regimens and without added&#xD;
      morbidity. The potential advantages include: 1) less time away from homes, families and jobs;&#xD;
      2) less cost associated with travel and time away from work; 3) ease the demand on radiation&#xD;
      treatment resources and produce savings to the health-care system. Moreover, treatment prone&#xD;
      assures that only minimal dose of radiation is delivered to the lung, heart and to the&#xD;
      controlateral breast.&#xD;
&#xD;
      Patients will have completed all breast surgical procedures prior to accrual into this&#xD;
      protocol in order to establish eligibility criteria. All patients will then be treated prone&#xD;
      with 2.7 Gy/fraction delivered in 15 fractions over a 3-week period for a total dose of 40.5&#xD;
      Gy.&#xD;
&#xD;
      All patients will be followed 1, 3, 6, 12 months after treatment course, then yearly&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2005</start_date>
  <completion_date type="Actual">June 2, 2017</completion_date>
  <primary_completion_date type="Actual">June 2, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Local Recurrence in Breast</measure>
    <time_frame>5 years</time_frame>
    <description>Defined by the discovery of invasive disease or DCIS in the same region of the breast after segmental mastectomy and radiation, by clinical or radiographic means.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Regional Recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Defined by the discovery of invasive disease or DCIS regional recurrence in the lymph node after segmental mastectomy and radiation, by clinical or radiographic means.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Contralateral Breast Cancer</measure>
    <time_frame>5 years</time_frame>
    <description>Defined by the discovery of contra-lateral breast cancer after segmental mastectomy and radiation, by clinical or radio-graphic means.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Distant Metastases</measure>
    <time_frame>5 years</time_frame>
    <description>number of participants found to have distant metastases after segmental mastectomy and radiation, by clinical or radiographic means</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an Outcome of Death</measure>
    <time_frame>5 years</time_frame>
    <description>Overall 5-Year cumulative rate of death based on Kaplan-Meier Analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Grade Late Radiation Toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>Measure of treatment related late toxicities at or more than 6 months after completion of radiation therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Self-assessment of the Cosmetic Results</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">314</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Accelerated intensity modulated radiation therapy (AIMRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Accelerated intensity modulated radiation therapy (AIMRT)</intervention_name>
    <arm_group_label>Accelerated intensity modulated radiation therapy (AIMRT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pre- or post-menopausal women with Stage I and II breast cancer&#xD;
&#xD;
          -  Biopsy-proven invasive breast cancer, excised with negative margins of at least 1 mm&#xD;
&#xD;
          -  Status post segmental mastectomy. and after sentinel node biopsy and/or axillary node&#xD;
             dissection&#xD;
&#xD;
          -  At least 2 weeks from last chemotherapy&#xD;
&#xD;
          -  Tumors &lt; 5 mm do not require nodal assessment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous radiation therapy to the ipsilateral breast.&#xD;
&#xD;
          -  More than 3 involved nodes identified at axillary staging, requiring adjuvant axillary&#xD;
             radiation.&#xD;
&#xD;
          -  Active connective tissue disorders, such as lupus or scleroderma.&#xD;
&#xD;
          -  Prior or concurrent malignancy other than basal or squamous cell skin cancer or&#xD;
             carcinoma in-situ of the cervix, unless disease-free &gt; 5 years.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Perez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <results_first_submitted>August 31, 2017</results_first_submitted>
  <results_first_submitted_qc>July 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 14, 2020</results_first_posted>
  <last_update_submitted>July 31, 2020</last_update_submitted>
  <last_update_submitted_qc>July 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Accelerated Intensity Modulated Radiation Therapy (AIMRT)</title>
          <description>All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.&#xD;
Accelerated intensity modulated radiation therapy (AIMRT)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="314"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="314"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Accelerated Intensity Modulated Radiation Therapy (AIMRT)</title>
          <description>All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.&#xD;
Accelerated intensity modulated radiation therapy (AIMRT)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="314"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Local Recurrence in Breast</title>
        <description>Defined by the discovery of invasive disease or DCIS in the same region of the breast after segmental mastectomy and radiation, by clinical or radiographic means.</description>
        <time_frame>5 years</time_frame>
        <population>Risk rate at 5 years</population>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Intensity Modulated Radiation Therapy (AIMRT)</title>
            <description>All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.&#xD;
Accelerated intensity modulated radiation therapy (AIMRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local Recurrence in Breast</title>
          <description>Defined by the discovery of invasive disease or DCIS in the same region of the breast after segmental mastectomy and radiation, by clinical or radiographic means.</description>
          <population>Risk rate at 5 years</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Regional Recurrence</title>
        <description>Defined by the discovery of invasive disease or DCIS regional recurrence in the lymph node after segmental mastectomy and radiation, by clinical or radiographic means.</description>
        <time_frame>5 years</time_frame>
        <population>Risk rate at 5 years</population>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Intensity Modulated Radiation Therapy (AIMRT)</title>
            <description>All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.&#xD;
Accelerated intensity modulated radiation therapy (AIMRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Regional Recurrence</title>
          <description>Defined by the discovery of invasive disease or DCIS regional recurrence in the lymph node after segmental mastectomy and radiation, by clinical or radiographic means.</description>
          <population>Risk rate at 5 years</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Contralateral Breast Cancer</title>
        <description>Defined by the discovery of contra-lateral breast cancer after segmental mastectomy and radiation, by clinical or radio-graphic means.</description>
        <time_frame>5 years</time_frame>
        <population>Risk rate at 5 years</population>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Intensity Modulated Radiation Therapy (AIMRT)</title>
            <description>All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.&#xD;
Accelerated intensity modulated radiation therapy (AIMRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Contralateral Breast Cancer</title>
          <description>Defined by the discovery of contra-lateral breast cancer after segmental mastectomy and radiation, by clinical or radio-graphic means.</description>
          <population>Risk rate at 5 years</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Distant Metastases</title>
        <description>number of participants found to have distant metastases after segmental mastectomy and radiation, by clinical or radiographic means</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Intensity Modulated Radiation Therapy (AIMRT)</title>
            <description>All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.&#xD;
Accelerated intensity modulated radiation therapy (AIMRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Distant Metastases</title>
          <description>number of participants found to have distant metastases after segmental mastectomy and radiation, by clinical or radiographic means</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Outcome of Death</title>
        <description>Overall 5-Year cumulative rate of death based on Kaplan-Meier Analysis</description>
        <time_frame>5 years</time_frame>
        <population>Risk rate at 5 years</population>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Intensity Modulated Radiation Therapy (AIMRT)</title>
            <description>All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.&#xD;
Accelerated intensity modulated radiation therapy (AIMRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Outcome of Death</title>
          <description>Overall 5-Year cumulative rate of death based on Kaplan-Meier Analysis</description>
          <population>Risk rate at 5 years</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Grade Late Radiation Toxicity</title>
        <description>Measure of treatment related late toxicities at or more than 6 months after completion of radiation therapy.</description>
        <time_frame>5 years</time_frame>
        <population>Overall, 314 participants were analyzed for each of the below listed toxicities, by grade. The numbers are broken down to toxicity and grade for each row. In total these numbers add to 314</population>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Intensity Modulated Radiation Therapy (AIMRT)</title>
            <description>All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.&#xD;
Accelerated intensity modulated radiation therapy (AIMRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Grade Late Radiation Toxicity</title>
          <description>Measure of treatment related late toxicities at or more than 6 months after completion of radiation therapy.</description>
          <population>Overall, 314 participants were analyzed for each of the below listed toxicities, by grade. The numbers are broken down to toxicity and grade for each row. In total these numbers add to 314</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pigmentation Change</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast Fibrosis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast Retraction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast Telangiectasia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast Edema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast Pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arm Lymphadema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Self-assessment of the Cosmetic Results</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Intensity Modulated Radiation Therapy (AIMRT)</title>
            <description>All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.&#xD;
Accelerated intensity modulated radiation therapy (AIMRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Self-assessment of the Cosmetic Results</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Excellent/Good</title>
                  <measurement_list>
                    <measurement group_id="O1" value="251"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fair</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poor</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Accelerated Intensity Modulated Radiation Therapy (AIMRT)</title>
            <description>All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.&#xD;
Accelerated intensity modulated radiation therapy (AIMRT)</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <units>percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 Years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Accelerated Intensity Modulated Radiation Therapy (AIMRT)</title>
          <description>All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.&#xD;
Accelerated intensity modulated radiation therapy (AIMRT)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolitic autoimmune anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>MELANOMA IN SITU RIGTH LEG</sub_title>
                <description>MELANOMA IN SITU RIGTH LEG</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PEDAL EDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>SYNCOPAL EPISODE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>RIGHT LEG SURGERY FOR STENT PLACEMENT</sub_title>
                <description>Cardiovascular / General Other: RIGHT LEG SURGERY FOR STENT PLACEMENT</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>Cardiovascular / General Other: SPLENIC HEMANGIOMA</sub_title>
                <description>Cardiovascular / General Other: SPLENIC HEMANGIOMA</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>ADRENAL CORTICAL ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>NIGHT SWEATS</sub_title>
                <description>NIGHT SWEATS</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN BONE</sub_title>
                <description>Hot flashes</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <description>NAUSEA</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>WEIGHT GAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>WEIGHT GAIN</sub_title>
                <description>WEIGHT GAIN</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>WEIGHT LOSS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>HAIR THINNING</sub_title>
                <description>HAIR THINNING</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>INCREASED LIVER ENZYMES</sub_title>
                <description>INCREASED LIVER ENZYMES</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>LYMPHEDEMA ARM LEFT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>MASTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>CELLULITIS RIGHT ARM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>ARTHRITIS LEG PAIN</sub_title>
                <description>ARTHRITIS LEG PAIN+ CLAUDICATIO INTERMITTENS</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>DEGENERATIVE SPONDILOSIS</sub_title>
                <description>Musculoskeletal Other: DEGENERATIVE SPONDILOSIS</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>FRACTURE 2ND LEFT RIB</sub_title>
                <description>FRACTURE 2ND LEFT RIB</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>LEFT FRACTURE ARM LEFT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>JOINT STIFFNESS, CARPAL TUNNEL SYNDROME</sub_title>
                <description>JOINT STIFFNESS, CARPAL TUNNEL SYNDROME</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>ARTHRITIS RIGHT WRIST</sub_title>
                <description>ARTHRITIS RIGHT WRIST</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Second Malignancy Invasive ductal ca</sub_title>
                <description>Second Malignancy Invasive ductal ca of controlateral breast (RB)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>Second Malignancy NEW PRIMARY AT LEFT BREAST</sub_title>
                <description>Second Malignancy NEW PRIMARY AT LEFT BREAST</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>Second Malignancy RIGHT ANKLE MELANOMA</sub_title>
                <description>Second Malignancy RIGHT ANKLE MELANOMA</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN lower extremities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN Breast Left superior aspect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN RIGHT SHOULDER+ LEFT HIP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>Pain ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN BACK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN LEFT BREAST AT INCISION SITE sore</sub_title>
                <description>PAIN LEFT BREAST AT INCISION SITE sore</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <description>HEADACHE</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>Pain ARTHRALGIA GENERALIZED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <description>DIZZINESS</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN BACK</sub_title>
                <description>PAIN BACK</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN AXILLA BOTH</sub_title>
                <description>PAIN AXILLA BOTH</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN LEFT SHOULDER</sub_title>
                <description>PAIN LEFT SHOULDER</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <description>Pain ARTHRALGIA</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN RIGHT THIGH</sub_title>
                <description>PAIN RIGHT THIGH</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>NUMBNESS</sub_title>
                <description>PINS AND NEEDLES /NUMBNESS AT SENTINEL NODES SITE</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN LEFT BREAST</sub_title>
                <description>PAIN LEFT BREAST ON DEEP PALPATION</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN BREAST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN BACK LOWER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>MENINGIOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>MEMORY LOSS/UNSTEADINESS (DUE TO MENINGIOMA)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN BONE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN ARM LEFT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN LEFT SHOULDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>Pain ARTHRALGIA</sub_title>
                <description>Pain ARTHRALGIA</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <description>MYALGIA</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN SCAR</sub_title>
                <description>PAIN SCAR</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN Arthralgia KNEE B/L</sub_title>
                <description>PAIN Arthralgia KNEE B/L</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PARESTHESIA ARM LEFT</sub_title>
                <description>PARESTHESIA ARM LEFT</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>Pain ARTHRALGIA - Occasional</sub_title>
                <description>Pain ARTHRALGIA - Occasional</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN BACK LOWER</sub_title>
                <description>PAIN BACK LOWER</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN RIGHT RIB AREA</sub_title>
                <description>PAIN RIGHT RIB AREA</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PAIN RIGHT THUMB severe</sub_title>
                <description>PAIN RIGHT THUMB severe</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>RASH BOTH BREASTS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>Eczema at right inframammary breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>DERMATITIS HANDS AND FEET</sub_title>
                <description>Second Malignancy Globular ca in situ with Pagetoid spread in controlateral breast</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>RASH FUNGAL - LEFT AXILLA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>DERMATITIS HANDS AND FEET</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>HAIR THINNING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PRURITIS AT BREAST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>Secondary malignancySKIN CANCER (LEG)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>SEBORRHOIC KERATOSIS UNDER RIGHT BREAST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <description>PRURITUS</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="314"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carmen Perez, MD</name_or_title>
      <organization>New York University School of Medicine</organization>
      <phone>212 731 5003</phone>
      <email>carmen.perez@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

